Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer

Drugs and Aging

Volumn 13, Issue 4, 1998, Pages 321-332

  Wiseman, Lynda R ^a   Adkins, Julie C ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; MEGESTROL;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BACKACHE; BONE PAIN; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EDEMA; ESTROGEN BLOOD LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; VOMITING; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; NITRILES; POSTMENOPAUSE; TREATMENT OUTCOME; TRIAZOLES;

EID: 0031756905     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199813040-00008     Document Type: Review

References (34)

1. Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13 (2): 513-29
2. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 1998; 4: 527-34
3. Goss PE, Gwyn KMEH. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 1994 Nov; 12: 2460-70
4. Leonard RCF, Rodger A, Dixon JM. Metastatic breast cancer. BMJ 1994 Dec; 309: 1501-4
5. Dowsett M. Biological background to aromatase inhibition. Breast 1996; 5 (3): 196-201
6. Miller WR. Aromatase inhibitors and breast cancer. Cancer Treat Rev 1997; 23: 171-87
7. Coombes RC, Goss PE, Dowsett M. et al. 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids 1987 Jul-Sep; 50: 245-52
8. Harris AL, Powles TJ, Smith IE, et al. Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 1983; 19: 11-7
9. Wiseman LR, Goa KL. Formestane: a review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Drugs Aging 1996 Oct; 9 (4): 292-306
10. Plourde PV, Dyroff M, Dukes M. Arimidex®: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994; 30 (1): 103-11
11. Dukes M, Edwards PN, Large M, et al. The preclinical pharmacology of Arimidex (anastrozole: ZD1033): a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 1996; 58 (4): 439-45
12. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74: 1286-91
13. Dowsett M, Lonning PE. Anastrozole- a new generation in aromatase inhibition: clinical pharmacology. Oncology 1997; 54 Suppl. 2: 11-4
14. Yates RA, Dowsett M, Fisher GV, et al. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996 Feb; 73: 543-8
15. Lønning PE, Geisler J, King N, et al. Influence of Arimidex (anastrozole). a non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in postmenopausal women with breast cancer [abstract]. Breast Cancel Res Treat 1996; 37 Suppl.: 72
16. Kleeberg UR, Dowsett M, Carrion RP, et al. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer. Oncology 1997; 54 Suppl. 2: 19-22
17. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer A 1996 Mar; 32A: 404-12
18. Dowsett M, Welch H, Blackman GM, et al. A randomised, double-blind, parallel-group trial to evaluate the effect of Arimidex (anastrozole) on the pharmacokinetics of tamoxifen in postmenopausal breast cancer patients [abstract]. Breast 1997 Aug; 6 (4): 245
19. Brodic A, Qing L, Yang L, et al. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology 1998; 12: 36-40
20. Wolter J, Robert N, Harvey H, et al. Arimidex (ZD1013): a phase I study of a new, selective orally active aromatase inhibitor in postmenopausal women with advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 119
21. Plourde PV, Yates RA, Dyroff M, et al. The effect of Arimidex™, a new potent aromatase inhibitor, on circulating estrogens in post-menopausal women [abstract]. Proc Am Soc Clin Oncol 1993 Mar; 12: 91
22. Anastrozole. PDR Generics, 4th ed., Medical Economics. New Jersey, 1998: 198-200
23. Baldinger SL, DeFusco P. Focus on anastrozole: an aromatase inhibitor for the treatment of hormonally dependent advanced breast cancer. Formulary 1996 May; 31: 363-73
24. Bioavailability of Arimidex: effect of food and comparison of bioavailability of Arimidex tablet and an oral solution. Data for Clinical Invetigators 5th Ed., Jun 1995, Chester, England. Zeneca (Data on file)
25. Metabolism of anastrozole in healthy postmenopausal female volunteers. Data for Clinical Investigators 5th Ed., Jun 1995. Chester, England. Zeneca (Data on file)
26. Predictable pharmacokinetics of Arimidex when administered orally for periods of up to seventy-six weeks. Arimidex Pharmacology Summary Report, Chester, England. Zeneca (Data on file)
27. Zeneca Pharma. Arimidex™. ABPI Compendium of Data Sheets and Summaries of Product Characteristics. Datapharm publications Limited, London, 1507
28. Dowsett M, Yates R, Wong YWJ, et al. Arimidex (anastrozole): lack of interactions with tamoxifen, antipyrine, cimetidine and warfarin [abstract]. Eur J Cancer 1998 Feb; 34 Suppl. 1: S39-40
29. Buzdar AU, Jones SE, Vogel CL, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997; 79: 730-9
30. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in postmenopausal women with advanced breast cancer: results of a survival update based on a combined analysis of data from 2 mature phase III trials. Cancer. In press
31. Hayward JL, Carbone PP, Henson JC, et al. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89-94
32. de Haes JCJM, van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034-8
33. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996 Jul; 14: 2000-11
34. Baum M, Houghton J, On behalf of the ATAC Steering Committee UK. Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer [abstract]. Eur J Cancer 1998 Feb; 34 Suppl. 1: S39